Hodgkin's Disease

References

• Longo D., Duffey P., Hubbard S, Young R., DeVita V. Radiation therapy is better than chemotherapy in early-stage Hodgkin's disease? Not so fast. J Clin Oncol 1992; 10: 1367–9, (02)
   PubMed Web of Science ®Google Scholar
• Henry-Amar M., Somers R. Survival outcome after Hodgkin's disease: A report from the international data base on Hodgkin's disease. Semin Oncol 1990; 17: 758–68, (R1/ 14 225)
   PubMed Web of Science ®Google Scholar
• Tubiana M., Henry-Amar M., Carde P., et al. Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin's disease. The EORTC Lymphoma Group controlled clinical trials: 1964–1987. Blood 1989; 73: 47–56, (C1/1 579)
   PubMed Web of Science ®Google Scholar
• Bonfante V., Santoro A, Viviani S., et al. Early stage Hodgkin's disease: Ten-year results of a non-randomized study with radiotherapy alone or combined with MOPP. Eur J Cancer 1993; 29A: 24–9, (P2/201)
   Google Scholar
• Carde P., Burgers J, Henry-Amar M., et al. Clinical stages I and II Hodgkin's disease: A specifically tailored therapy according to prognostic factors. J Clin Oncol 1988; 6: 239–52, (C1/494)
   PubMed Web of Science ®Google Scholar
• Mandelli F., Anselmo A., Cartoni C., Cimino G., Maurizi Enrici R., Biagini C. Evaluation of therapeutic modalities in the control of Hodgkin's disease. Int J Radiat Oncol Biol Phys 1986; 12: 1617–20, (R3/58)
   PubMed Web of Science ®Google Scholar
• Lee C., Aeppli D., Bloomfield C., Levitt S. Curative radiotherapy for laparotomy-staged IA, IIA, IIIA Hodgkin's disease: An evaluation of the gains achieved with radical radiotherapy. Int J Radiat Oncol Biol Phys 1990; 19: 547–59, (P2/ 179)
   PubMed Web of Science ®Google Scholar
• Gospodarowicz M., Sutcliffe S., Bergsage D, Chua T. Radiation therapy in clinical stage I and II Hodgkin's disease. Eur J Cancer 1992; 28A: 1841–6, (R1/731)
   PubMed Web of Science ®Google Scholar
• Roach M., Brophy N., Cox R., Varghese A, Hoppe R. Prognostic factors for patients relapsing after radiotherapy for early-stage Hodgkin's disease. J Clin Oncol 1990; 8: 623–9, (R1/109)
   PubMed Web of Science ®Google Scholar
• Healey E., Tarbell N., Kalish L., et al. Prognostic factors for patients with Hodgkin disease in first relapse. Cancer 1993; 71: 2613–20, (R1/627)
   PubMed Web of Science ®Google Scholar
• Hartsell W., Sarin P., Recine D., et al. Long-term results of curative irradiation in pathologically staged IA and IIA Hodgkin's disease. Radiol 1993; 186: 565–8, (R1/176)
   PubMed Web of Science ®Google Scholar
• Wasserman T., Trenkner D., Fineberg B, Kucik N. Cure of early-stage Hodgkin's disease with subtotal nodal irradiation. Cancer 1991; 68: 1208–15, (R2/94)
   PubMed Web of Science ®Google Scholar
• Mauch P., Tarbell N., Weinstein H., et al. Stage IA and HA supradiaphragmatic Hodgkin's disease: Prognostic factors in surgically staged patients treated with mantle and paraaortic irradiation. J Clin Oncol 1988; 6: 1576–83, (R1/315)
   PubMed Web of Science ®Google Scholar
• Vinciguerra V., Propert K., Coleman M., et al. Alternating cycles of combination chemotherapy for patients with recurrent Hodgkin's disease following radiotherapy. A prospective randomized study by the cancer and leukemia group B. J Clin Oncol 1986; 4: 838–46, (C2/113)
   PubMed Web of Science ®Google Scholar
• Hoppe R. Radiation therapy in the management of Hodgkin's disease. Semin Oncol 1990; 17: 704–15, (L1)
   PubMed Web of Science ®Google Scholar
• Haybittle J., Easterling M., Bennett M., et al. Review of British national lymphoma investigation studies of Hodgkin's disease and development of prognostic index. Lancet 1985; April 27: 967–72, (C1/743)
   Google Scholar
• Rosenberg S., Kaplan H. The evolution and summary results of the Stanford randomized clinical trials of the management of Hodgkin's disease: 1962–1984. Int J Radiat Oncol Biol Phys 1985; 11: 5–22, (C2/835)
   PubMed Web of Science ®Google Scholar
• Shore T., Nelson N., Weinerman B. A meta-analysis of stages I and II Hodgkin's disease. Cancer 1990; 65: 1155–60, (M2/2 999))
   PubMed Web of Science ®Google Scholar
• Radiotherapy of stage I and II Hodgkin's disease. A collaborative study. Cancer 1984; 54: 1928–42, (C1/460)
   PubMedGoogle Scholar
• Farah R., Ultmann J., Griem M., et al. Extended mantle radiation therapy for pathologic stage I and II Hodgkin's disease. J Clin Oncol 1988; 6: 1047–52, (R2/135)
   PubMed Web of Science ®Google Scholar
• Mendenhall N., Taylor B, Marcus R., Million R. The impact of pelvic recurrence and elective pelvic irradiation on survival and treatment morbidity in early-stage Hodgkin's disease. Int J Radiat Oncol Biol Phys 1991; 21: 1157–65, (R3/153)
   PubMed Web of Science ®Google Scholar
• Cosset M., Henry-Amar M., Meerwaldt J., et al. The EORTC trials for limited stage Hodgkin's disease. Eur J Cancer 1992; 28A: 1847–50, (C1/1641)
   PubMed Web of Science ®Google Scholar
• Ganesan T., Wrigley P., Murray P., et al. Radiotherapy for stage I Hodgkin's disease: 20 years experience at St Bartholomew's Hospital. Br J Cancer 1990; 62: 314–8, (R2/ 90)
   PubMed Web of Science ®Google Scholar
• Anderson H., Deakin D., Wagstaff J., et al. A randomised study of adjuvant chemotherapy after mantle radiotherapy in supradiaphragmatic Hodgkin's disease PS IA-IIB: A report from the Manchester Lymphoma Group. Br J Cancer 1984; 49: 695–702, (C2/114)
   PubMed Web of Science ®Google Scholar
• Andrieu J-M, Dana M., Desprez-Curely J-P., Jacquillat C., Weil M. MOPP chemotherapy plus irradiation for Hodgkin's disease, stages IA to IIIB. Long-term results of the prospective trial H72 (1972–1976, 334 patients). Hema-tol Oncol 1985; 3: 219–31, (P2/334))
   PubMed Web of Science ®Google Scholar
• Crnkovich M., Hoppe R., Rosenberg S. Stage IIB Hodgkin's disease: The Stanford experience. J Clin Oncol 1986; 4: 472–9, (R3/126)
   PubMed Web of Science ®Google Scholar
• Zittoun R., Audebert A., Hoerni B., et al. Extended versus involved fields irradiation combined with MOPP chemotherapy in early clinical stages of Hodgkin's disease. J Clin Oncol 1985; 3: 207–14, (C2/335)
   PubMed Web of Science ®Google Scholar
• Biti G., Cimino G., Cartoni C., et al. Extended-field radiotherapy is superior to MOPP chemotherapy for the treatment of pathologic stage I-IIA Hodgkin's disease: Eight-year update of an Italian prospective randomized study. J Clin Oncol 1992; 10: 378–82, (C2/89)
   PubMed Web of Science ®Google Scholar
• Cimino G., Biti G., Cartoni C., Magrini S. Chemotherapy versus radiotherapy in early-stage Hodgkin's disease: Evidence of a more difficult rescue for patients relapsed after chemotherapy. Eur J Cancer 1992; 28A: 1853–5, (C2/89)
   PubMed Web of Science ®Google Scholar
• Longo D., Glatstein E., Duffey P., et al. Radiation therapy versus combination chemotherapy in the treatment of early-stage Hodgkin's disease: Seven-year results of a prospective randomized trial. J Clin Oncol 1991; 9: 906–17, (C2/87)
   PubMed Web of Science ®Google Scholar
• Anselmo A., Bove M., Cartoni C., et al. Combined modality (ABVD plus radiotherapy) versus radiotherapy in the management of early stage (IIA) Hodgkin's disease with mediastinal involvement. Haematol 1992; 77: 177–9, (C3/73)
   PubMed Web of Science ®Google Scholar
• Straus D., Yahalom J, Gaynor J., et al. Four cycles of chemotherapy and regional radiation therapy for clinical early-stage and intermediate-stage Hodgkin's disease. Cancer 1992; 69: 1052–60, (C2/I20)
   PubMed Web of Science ®Google Scholar
• Nordentoft A., Nissen N., Bjørn Jensen K. Experiences from the national Danish Hodgkin's study group (LYGRA) with respect to diagnosis classification and treatment of Hodgkin's disease. Acta Radiol Oncol 1984; 23: 163–7, (C1/310)
   PubMed Web of Science ®Google Scholar
• Specht L., Carde P., Mauch P., Magrini S., Santarelli M. Radiotherapy versus combined modality in early stages. Ann Oncol 1992; 3((Suppl 4))77–81, (M2/2 069)
   PubMedGoogle Scholar
• Horning S., Hoppe R., Hancock S., Rosenberg S. Vinblastine bleomycin and methotrexate: An effective adjuvant in favorable Hodgkin's disease. J Clin Oncol 1988; 6: 1822–31, (C3/67)
   PubMed Web of Science ®Google Scholar
• Pavlovsky S., Maschio M., Santarelli M., et al. Randomized trial of chemotherapy versus chemotherapy plus radiotherapy for stage I-II Hodgkin's disease. J Natl Cancer Inst 1988; 80: 1466–73, (C2/277)
   PubMed Web of Science ®Google Scholar
• Bessel E., MacLennan K., Toghill P., Ellis I., Fletcher J., Dowling F. Suprahyoid Hodgkin's disease stage IA. Radio-ther Oncol 1991; 22: 190–4, (R2/71)
   PubMed Web of Science ®Google Scholar
• Gospodarowicz M., Sutcliffe S., Clark R., et al. Analysis of supradiaphragmatic clinical stage I and II Hodgkin's disease treated with radiation alone. Int J Radiat Oncol Biol Phys 1992; 22: 859–65, (R1/250)
   PubMed Web of Science ®Google Scholar
• Urba W., Longo D. Hodgkin's disease. N Engl J Med 1992; 326: 678–87, (L1)
   PubMed Web of Science ®Google Scholar
• Levitt S., Lee C., Aeppli D., Lindgren B, Peterson B. The role of radiation therapy in Hodgkin disease: Experience and controversy. The 54th annual Janeway lecture: 1989. Cancer 1992; 70: 693–703, (P2/I79)
   PubMed Web of Science ®Google Scholar
• Tarbell N., Thompson L., Mauch P. Thoracic irradiation in Hodgkin's disease: Disease control and long-term complications. Int J Radiat Oncol Biol Phys 1990; 18: 275–81, (Rl/590)
   PubMed Web of Science ®Google Scholar
• Orlandi E., Lazzarino M, Brusamolino E., et al. Residual mediastinal widening following therapy in Hodgkin's disease. Hematol Oncol 1990; 8: 125–31, (R2/102)
   PubMed Web of Science ®Google Scholar
• Radford J., Cowan R., Flanagan M., et al. The significance of residual mediastinal abnormality on the chest radiograph following treatment for Hodgkin's disease. J Clin Oncol 1988; 6: 940–6, (R2/110)
   PubMed Web of Science ®Google Scholar
• Leopold K., Canellos G., Rosenthal D., Shulman L., Weinstein H., Mauch P. Stage IA IIB Hodgkin's disease: Staging and treatment of patients with large mediastinal adenopathy. J Clin Oncol 1989; 7: 1059–65, (R2/92)
   PubMed Web of Science ®Google Scholar
• Zinzani P., Mazza P, Gherlinzoni F., et al. Massive mediastinal involvement in stage I - II Hodgkin's disease: Response to combined modality treatment. Leuk Lymph 1992; 8: 81–5, (P2/37)
   PubMed Web of Science ®Google Scholar
• Longo D., Russo A., Duffey P., et al. Treatment of advanced-stage massive mediastinal Hodgkin's disease: The case for combined modality treatment. J Clin Oncol 1991; 9: 227–35, (R3/49)
   PubMed Web of Science ®Google Scholar
• Dowling S., Peschel R., Portlock C., Kramer C, Farber L., Knowlton A. Mediastinal irradiation in combined modality therapy for Hodgkin's disease. Int J Radiat Oncol Biol Phys 1990; 19: 543–6, (R3/50)
   PubMed Web of Science ®Google Scholar
• Chen J., Osborne B., Butler J. Residual fibrous masses in treated Hodgkin's disease. Cancer 1987; 60: 407–13, (R3/5)
   PubMed Web of Science ®Google Scholar
• Hoppe R. The management of stage II Hodgkin's disease with a large mediastinal mass: A prospective program emphasizing irradiation. Int J Radiat Oncol Biol Phys 1985; 11: 349–55, (R3/13)
   PubMed Web of Science ®Google Scholar
• Givens S., Fuller L., Hagemeister F., Gehan E. Treatment of lower torso stages I and II Hodgkin's disease with radiation with or without adjuvant Mechlorethamine, Vincristine, Procarbazine, and Prednisone. Cancer 1990; 66: 69–74, (R2/60)
   PubMed Web of Science ®Google Scholar
• Krikorian J., Portlock C., Mauch P. Hodgkin's disease presenting below the diaphragm: A review. J Clin Oncol 1986; 4: 1551–62, (L2)
   PubMed Web of Science ®Google Scholar
• Mauch P., Greenberg H., Lewin A., Cassady R., Weichselbaum R., Hellman S. Prognostic factors in patients with subdiaphragmatic Hodgkin's disease. Hematol Oncol 1983; 1: 205–14, (R3/36)
   PubMedGoogle Scholar
• Mason M., Law M., Ashley S., et al. Infradiaphragmatic Hodgkin's disease. Eur J Cancer 1992; 28A: 1851–2, (R3/53)
   PubMed Web of Science ®Google Scholar
• Frassica D., Schomberg P, Banks P., Colgan J., Ilstrup D., Earle J. Management of subdiaphragmatic early-stage Hodgkin's disease. Int J Radiat Oncol Biol Phys 1989; 16: 1459–63, (R3/26)
   PubMed Web of Science ®Google Scholar
• Hou-Wun Mai D., Peschel R., Portlock C., Knowlton A., Farber L. Stage I and II subdiaphragmatic Hodgkin's disease. Cancer 1991; 68: 1476–81, (R3/19)
   PubMed Web of Science ®Google Scholar
• Leibenhaut M., Hoppe R., Varghese A., Rosenberg S. Subdiaphragmatic Hodgkin's disease: Laparotomy and treatment results in 49 patients. J Clin Oncol 1987; 5: 1050–5, (R2/49)
   PubMed Web of Science ®Google Scholar
• Mauch P., Goffman T., Rosenthal D., Canellos G., Come S., Hellman S. Stage III Hodgkin's disease: Improved survival with combined modality therapy as compared with radiation therapy alone. J Clin Oncol 1985; 3: 1166–73, (R2/120)
   PubMed Web of Science ®Google Scholar
• Prosnitz L., Cooper D., Cox E., Kapp D., Farber L. Treatment selection for stage IIIA Hodgkin's disease patients. Int J Radiat Oncol Biol Phys 1985; II: 1431–7, (R2/85)
   Google Scholar
• Brada M., Ashley S., Nicholls J., et al. Stage III Hodgkin's disease-long term results following chemotherapy radiotherapy and combined modality therapy. Radiother Oncol 1989; 14: 185–98, (R2/215)
   PubMed Web of Science ®Google Scholar
• Stein R., Golomb H., Wiernik P., et al. Anatomic substages of stage IIIA Hodgkin's disease: Followup of a collaborative study. Cancer Treat Rep 1982; 66: 733–41, (R2/130)
   PubMedGoogle Scholar
• Oza A., Leahy M., Lim J., et al. The treatment of stage IIIA Hodgkin's disease-total nodal irradiation versus combination chemotherapy: Either or neither. J Clin Oncol 1991; 9: 1514–6, (R2/85)
   PubMed Web of Science ®Google Scholar
• Horning S., Ang P., Hoppe R., Rosenberg S. The Stanford experience with combined procarbazine. Alkeran and vinblastine (PAVe) and radiotherapy for locally extensive and advanced stage Hodgkin's disease. Ann Oncol 1992; 3: 747–54, (R2/117)
   PubMed Web of Science ®Google Scholar
• Willett C., Linggood R., Meyer J., et al. Results of treatment of stage 3A Hodgkin's disease. Cancer 1987; 59: 27–30, (R3/38)
   PubMed Web of Science ®Google Scholar
• Henkelmann G., Hagemeister F., Fuller L. Two cycles of MOPP and radiotherapy for stage III 1A and stage HUB Hodgkin's disease. J Clin Oncol 1988; 6: 1293–1302, (R2/76)
   PubMed Web of Science ®Google Scholar
• Crowther D., Wagstaff J., Deakin D., et al. A randomized study comparing chemotherapy alone with chemotherapy followed by radiotherapy in patients with pathologically staged IIIA Hodgkin's disease. J Clin Oncol 1984; 2: 892–7, (C2/56)
   PubMed Web of Science ®Google Scholar
• Oza A., Ganesan T, Dorreen M., et al. Patterns of survival in patients with advanced Hodgkin's disease (HD) treated in a single centre over 20 years. Br J Cancer 1992; 65: 429–37, (R1/164)
   PubMed Web of Science ®Google Scholar
• Meerwaldt J., Coleman C., Fischer R., Lister T., Diehl V. Role of additional radiotherapy in advanced stages of Hodgkin's disease. Ann Oncol 1992; 3((Suppl 4))83–5, (L1)
   PubMedGoogle Scholar
• Hancock B., Vaughan Hudson G., Vaughan Hudson B., et al. British National Lymphoma Investigation randomised study of MOPP (mustine, Oncovin, procarbazine, prednisolone) against LOPP (Leukeran substituted for mustine) in advanced Hodgkin's disase-long term results. Br J Cancer 1991; 63: 579–82, (C1/290)
   PubMed Web of Science ®Google Scholar
• Sutcliffe S. Role of radiation therapy in advanced Hodgkin's disease-as yet an answer. Still a question? Ann Oncol 1992; 3: 499–501, (01)
   PubMed Web of Science ®Google Scholar
• Brizel D., Winer E., Prosnitz L., et al. Improved survival in advanced Hodgkin's disease with the use of combined modality therapy. Int J Radiat Oncol Biol Phys 1990; 19: 535–42, (R2/154)
   PubMed Web of Science ®Google Scholar
• Santoro A., Bonadonna G., Valagussa P., et al. Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: Superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol 1987; 5: 27–37, (C1/232)
   PubMed Web of Science ®Google Scholar
• Prosnitz L., Farber L., Kapp D., et al. Combined modality therapy for advanced Hodgkin's disease: 15-year follow-up data. J Clin Oncol 1988; 6: 603–12, (R2/184)
   PubMed Web of Science ®Google Scholar
• Yahalom J., Ryu J., Straus D., et al. Impact of adjuvant radiation of the patterns and rate of relapse in advanced-stage Hodgkin's disease treated with alternating chemotherapy combinations. J Clin Oncol 1991; 9: 2193–2201, (R2/222)
   PubMed Web of Science ®Google Scholar
• Yelle L., Bergsagel D., Basco V., et al. Combined modality therapy of Hodgkin's disease: 10-year results of National Cancer Institute of Canada Clinical Trials Group multicen-ter clinical trial. J Clin Oncol 1991; 9: 1983–93, (C2/226)
   PubMed Web of Science ®Google Scholar
• Pavlovsky S., Santarelli M., Sackman Muriel F., et al. Randomized trial of chemotherapy versus chemotherapy plus radiotherapy for stage III IV A & B Hodgkin's disease. Ann Oncol 1992; 3: 533–7, (C3/151)
   PubMed Web of Science ®Google Scholar
• Klimo P., Connors J. An update of the Vancouver experience in the management of advanced Hodgkin's disease treated with the MOPP/ABV hybrid program. Semin Hematol 1988; 2((Suppl 2))34–40, (R2/79)
   Google Scholar
• Roach M., Kapp D., Rosenberg S., Hoppe R. Radiotherapy with curative intent: An option in selected patients relapsing after chemotherapy for advanced Hodgkin's disease. J Clin Oncol 1987; 5: 550–5, (R3/13)
   PubMed Web of Science ®Google Scholar
• Hoppe R. The management of Hodgkin's disease in relapse after primary radiation therapy. Eur J Cancer 1992; 28A: 1920–2, (Rl/109)
   PubMed Web of Science ®Google Scholar
• Longo D., Duffey P., Young R., et al. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: The low probability for cure. J Clin Oncol 1992; 10: 210–8, (R2/107)
   PubMed Web of Science ®Google Scholar
• Viviani S., Santoro A., Negretti E., Bonfante V., Valagussa P., Bonadonna G. Salvage chemotherapy in Hodgkin's disease. Ann Oncol 1990; 1: 123–7, (R2/49)
   PubMed Web of Science ®Google Scholar
• Mauch P., Tarbell N., Skarin A., Rosenthal D., Weinstein H. Wide-field radiation therapy alone or with chemotherapy for Hodgkin's disease in relapse from combination chemotherapy. J Clin Oncol 1987; 5: 544–9, (R3/12)
   PubMed Web of Science ®Google Scholar
• Fox K., Lippman S., Cassady R., Heusinkveld R, Miller T. Radiation therapy salvage of Hodgkin's disease following chemotherapy failure. J Clin Oncol 1987; 5: 38–45, (R3/17)
   PubMed Web of Science ®Google Scholar
• Leigh B., Fox K., Mack C., Baier M., Miller T., Cassady R. Radiation therapy salvage of Hodgkin's disease following chemotherapy failure. Int J Radiat Oncol Biol Phys 1993; 27: 855–62, (R3/26)
   PubMed Web of Science ®Google Scholar
• Kirkove C., Timothy A. Radiotherapy as salvage treatment in patients with Hodgkin's disease of non-Hodgkin's lymphoma relapsing after initial chemotherapy. Hematol Oncol 1991; 9: 163–7, (R3/6)
   PubMed Web of Science ®Google Scholar
• Diehl L., Perry D., Terebelo H., et al. Radiation as salvage therapy for patients with Hodgkin's disease relapsing after MOPP (mechlorethamine, vincristine, prednisone, and procarbazine) chemotherapy. Cancer Treat Rep 1983; 67: 827–9, (R3/6)
   PubMedGoogle Scholar
• Salvagno L., Sorarù M, Aversa S., et al. Late relapses in Hodgkin's disease: Outcome of patients relapsing more than twelve months after primary chemotherapy. Ann Oncol 1993; 4: 657–62, (R2/40)
   PubMed Web of Science ®Google Scholar
• Brada M., Eeles R., Ashley S., Nichols J., Horwich A. Salvage radiotherapy in recurrent Hodgkin's disease. Ann Oncol 1992; 3: 131–5, (R3/44)
   PubMed Web of Science ®Google Scholar
• Armitage J. O. Early bone marrow transplantation in Hodgkin's disease. Ann Oncol 1994; 5((Suppl 2))161–3, (L1)
   PubMedGoogle Scholar
• DeVita V., Hellman S., Jaffe E. Hodgkin's disease. principles & practice of oncology, Cancer 1993; 1819–58, (L1)
   Google Scholar
• Sebag-Montefiore D., Maher E., Young J., Vaughan Hudson G., Hanks G. Variation in mantle technique: implications for establishing priorities for quality assurance in clinical trials. Radiother Oncol 1992; 23: 144–9, (Ol)
   PubMed Web of Science ®Google Scholar
• Krueck W., Hess C., Kortmann R, Bamberg M. Simultaneous supra- and infradiaphragmatic irradiation in Hodgkin's disease. Brit J Radiol 1993; 66: 703–10, (R2/68)
   PubMed Web of Science ®Google Scholar
• Kaplan H. Evidence for a tumoricidal dose level in the radiotherapy of Hodgkin's disease. Cancer Res 1966; 26: 1221–4, (Ol)
   PubMed Web of Science ®Google Scholar
• Fletcher G. Textbook of radiotherapy.3rdChapter 7: The lymphomatous diseases. Lea & Febiger, Philadelphia 1978, (L1)
   Google Scholar
• Vijayakumar S., Myrianthopoulos L. An updated dose-response analysis in Hodgkin's disease. Radiother Oncol 1992; 24: 1–13, (Ol)
   PubMed Web of Science ®Google Scholar
• Hanks G., Kinzie J., White R., Herring D., Kramer S. Patterns of care outcome studies. Results of the national practice in Hodgkin's disease. Cancer 1983; 51: 569–73, (R1/407)
   PubMed Web of Science ®Google Scholar
• Schewe K., Reavis J., Kun L., Cox J. Total dose fraction size and tumor volume in the local control of Hodgkin's disease. Int J Radiat Oncol Biol Phys 1988; 15: 25–8, (R2/112)
   PubMed Web of Science ®Google Scholar
• Schewe K., Kun L, Cox J. A step toward ending the controversies in Hodgkin's disease. Int J Radiat Oncol Biol Phys 1989; 17: 1123–4, (02)
   PubMed Web of Science ®Google Scholar
• Raubitschek A., Glatstein E. The never-ending controversies in Hodgkin's disease. Int J Radiat Oncol Biol Phys 1989; 17: 1115–7, (02)
   PubMed Web of Science ®Google Scholar
• Prosnitz L. Hodgkin's disease: The right dose. Int J Radiat Oncol Biol Phys 1990; 19: 803–4, (Ol)
   PubMed Web of Science ®Google Scholar
• Cosset J., Henry-Amar M., Meerwaldt J. Long-term toxicity of early stages of Hodgkin's disease therapy: The EORTC experience. Ann Oncol 1991; 2 (Suppl 2): 77–82, (R1/1 660)
   PubMed Web of Science ®Google Scholar
• Cosset J., Henry-Amar M., Girinski T., Malaise E., Dupouy N, Dutreix J. Late toxicity of radiotherapy in Hodgkin's disease. Acta Oncol 1988; 27: 123–9, (R1/140)
   PubMed Web of Science ®Google Scholar
• Henry-Amar M. Quantitative risk of second cancer in patients in first complete remission from early stages of Hodgkin's disease. NCI Monogr 1988; 6: 65–72, (R1/1 084)
   Google Scholar
• Fletcher G., Shukovsky L. The interpaly of radiocurability and tolerance in the irradiation of human cancers. J Radiol Electrol 1975; 56: 383–400, (Ol)
   PubMedGoogle Scholar
• Landberg T., Liden K., Forslo H. Split-course radiation therapy of mediastinal Hodgkin's disease. TSD and CRE concepts. Acta Radiol 1973; 12: 33–9, (02)
   Web of Science ®Google Scholar